Common Contracts
4 similar Sales Agreement contracts by Benitec Biopharma Inc., Immatics N.V., Neumora Therapeutics, Inc., ProQR Therapeutics N.V.
BENITEC BIOPHARMA INC. Shares of Common Stock ($0.0001 par value per share) SALES AGREEMENTSales Agreement • October 11th, 2024 • Benitec Biopharma Inc. • Pharmaceutical preparations • New York
Benitec Biopharma Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners LLC (the “Agent”), as follows:
IMMATICS N.V. Ordinary Shares (Nominal value €0.01 per share) SALES AGREEMENTSales Agreement • October 10th, 2024 • Immatics N.V. • Biological products, (no disgnostic substances) • New York
Immatics N.V., a public limited liability company (naamloze vennootschap) under Dutch law (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners LLC (the “Agent”), as follows:
Neumora Therapeutics, Inc. Shares of Common Stock ($0.0001 par value per share) SALES AGREEMENTSales Agreement • October 1st, 2024 • Neumora Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
Neumora Therapeutics, a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners LLC (the “Agent”), as follows:
PROQR THERAPEUTICS N.V. Ordinary Shares (nominal value €0.04 per share) Sales AgreementSales Agreement • September 30th, 2024 • ProQR Therapeutics N.V. • Pharmaceutical preparations • New York
ProQR Therapeutics N.V., a Dutch public company with limited liability (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as follows:
